Brought to you by:
SAVS reveals 2023–24 officeholders, including new president-elect
The Southern Association for Vascular Surgery (SAVS) officially announced its 2023–24 slate of officeholders following the conclusion of the recent SAVS annual business meeting. The member-only proceedings marked the conclusion of the 2022–23 presidency of William D. Jordan Jr., MD,…
New SVS series zeroes in on government’s impact on vascular surgery
Starting next month, the Society for Vascular Surgery (SVS) will begin a series of articles focusing on how the actions of Congress and regulatory agencies affect vascular surgeons and the patients they serve, and importantly, how sustained advocacy engagement is…
BEST-CLI: Analysis finds correlation between WIfI stage four CLTI and reports of poorer mental health
The BEST-CLI dataset has revealed a correlation between wounds, ischemia and foot infection (WIfI) stage and poorer quality of life due to mental, rather than physical, health for patients with chronic limb threatening ischemia (CLTI). Analyzing complete WIfI data from…
Surmodics provides regulatory update related to FDA premarket approval application for SurVeil
Surmodics recently announced it has received a letter from the Food and Drug Administration (FDA) related to its premarket approval (PMA) application for the SurVeil drug-coated balloon (DCB). In the letter, the FDA indicated that the application is not currently…
Bentley launches rebranded crossing catheter
Germany-based endovascular device company Bentley announced the launch of the BeBack crossing catheter—formerly known as the GoBack—designed for the treatment of heavily calcified lesions above and below the knee. Bentley acquired the catheter in September 2022 from Upstream Peripheral Technologies,…
Human-tissue engineered blood vessels remain durable at six years in PAD patients, latest study results show
Mid-term results from a phase II study of surgical bypass using the Human Acellular Vessel (HAV) demonstrated an overall secondary patency rate at 72 months of 60% measured by Kaplan Meier. There was no evidence of graft rejection or infection,…
JVS group: Further changes in store for 2023
The planned changes for 2023 for the Journal of Vascular Surgery publications continue the momentum that began in mid- 2022. As former Editor-in-Chief Peter Gloviczki, MD, and Senior Editor Peter Lawrence, MD, ended their six-year run as editors of all…
SVS unveils latest addition to JVS family of publications
The year 2023 promises to be one of change for the Journal of Vascular Surgery (JVS) family of publications, including the introduction of a fifth journal. JVS-Vascular Insights (JVS-VI) launched this month as an online-only, open-access (non-subscription) title. This model is…
SVS ends 2022 with latest ‘Week of Action’ to prevent Medicare payment reductions
The Society for Vascular Surgery (SVS) issued its thanks to December “Week of Action” participants. Once again, SVS members showed incredible support for the Society’s advocacy efforts by engaging in the week’s various activities and continuing to amplify the specialty’s…
SVS Foundation: ‘Gatsby’ Gala tickets on sale
Book your trip to the Roaring Twenties early, and save some money, perhaps for auction items. Early-bird ticket sales for the Society for Vascular Surgery (SVS) Foundation’s “Great Gatsby Gala,” to be held at the 2023 Vascular Annual Meeting (VAM), have…